Huifang Shan

Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.

Xinyu R. Ma, Yuanyuan Liu, Jie Yang, 2021, European journal of medicinal chemistry.

Discovery of 2-Methyl-2-(4-(2-methyl-8-(1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-naphtho[1,2-d]imidazol-1-yl)phenyl)propanenitrile as a Novel PI3K/mTOR Inhibitor with Enhanced Antitumor Efficacy In Vitro and In Vivo.

Rui Li, Yuanyuan Liu, Jie Yang, 2022, Journal of medicinal chemistry.

Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo.

Xinyu R. Ma, Yuanyuan Liu, Jie Yang, 2020, European journal of medicinal chemistry.

Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.

Rui Li, Lifeng Zhao, Jie Yang, 2019, European journal of medicinal chemistry.

Discovery of a PROTAC targeting ALK with in vivo activity.

Jie Yang, Meng Zhou, Rui Li, 2021, European journal of medicinal chemistry.

Development of PROTAC degrader probe of CDK4/6 based on DCAF16.

Rui Li, Hongjia Zhang, Qingjia Xu, 2023, Bioorganic chemistry.

Fabrication of Cu-doped molybdenum oxide for bifunctional SERS and photothermal conversion

Qingyong Tian, Huifang Shan, Wenjie Ma, 2022, Materials Chemistry and Physics.

Development of PROTAC degrader probe of CDK4/6 based on DCAF16.

Rui Li, Hongjia Zhang, Qingjia Xu, 2023, Bioorganic chemistry.